{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:11:32Z","timestamp":1770163892375,"version":"3.49.0"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) represents approximately 15% of all breast cancer diagnoses. Its heterogeneity and absence of targetable receptors make treatment particularly challenging, and it is burdened by a worse prognosis than other breast cancer subtypes. The absence of standardized care pathways may impede the accessibility of information for patients and caregivers. The present survey was conducted as part of a co-participatory process aimed at informing the development of a patient journey for TNBC. A group of statements was developed based on relevant literature, current guidelines, and good practice points (GPPs) for effective TNBC care and subsequently evaluated by a multi-stakeholder panel. Key steps in the care journey were then selected for the survey, and Coordinators of Italian BUs (65.4%) indicated the level of perceived importance and reported implementation of each item. Descriptive statistical analyses were employed. Despite some gaps concerning issues such as the involvement of general practitioners (GPs), data show agreement on perceived importance and generally adequate levels of reported implementation of core aspects of TNBC care, providing support for the development of an optimal care journey for triple-negative breast cancer patients grounded in real-world practice, which may help generate useful guidance where clear pathways are still lacking.<\/jats:p>","DOI":"10.3390\/curroncol33020083","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T10:48:01Z","timestamp":1770115681000},"page":"83","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2884-1632","authenticated-orcid":false,"given":"Nicla","family":"La Verde","sequence":"first","affiliation":[{"name":"Department of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, 20157 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0510-3559","authenticated-orcid":false,"given":"Luisa","family":"Brogonzoli","sequence":"additional","affiliation":[{"name":"The Bridge Foundation, 20144 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1838-7819","authenticated-orcid":false,"given":"Maria Silvia","family":"Cona","sequence":"additional","affiliation":[{"name":"Department of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, 20157 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-8561","authenticated-orcid":false,"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Iannelli","sequence":"additional","affiliation":[{"name":"Italian Federation of Volunteer-Based Cancer Organisations (FAVO), 00187 Rome, Italy"},{"name":"Italian Association for Cancer Patients, Relatives and Friends (AIMaC), 00187 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Massari","sequence":"additional","affiliation":[{"name":"The Bridge Foundation, 20144 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Panizza","sequence":"additional","affiliation":[{"name":"Breast Imaging Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Papa","sequence":"additional","affiliation":[{"name":"Department of Staff, University Hospital of Marche Region, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-4757","authenticated-orcid":false,"given":"Maria Carmela","family":"Piccirillo","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1635-5692","authenticated-orcid":false,"given":"Elisa","family":"Sala","sequence":"additional","affiliation":[{"name":"The Bridge Foundation, 20144 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio Mattia","family":"Scandali","sequence":"additional","affiliation":[{"name":"Hospital Medical Management, University Hospital of Marche Region, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Sgarella","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, IRCCS Policlinico S. Matteo Foundation University of Pavia, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Valentini","sequence":"additional","affiliation":[{"name":"The Bridge Foundation, 20144 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8474-644X","authenticated-orcid":false,"given":"Rosaria","family":"Iardino","sequence":"additional","affiliation":[{"name":"The Bridge Foundation, 20144 Milan, Italy"},{"name":"Bridge for Future Research Centre, University of Pavia, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"AIOM (2025, November 14). I Numeri del Cancro in Italia. Available online: https:\/\/www.aiom.it\/i-numeri-del-cancro-in-italia\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An Overview of Triple-Negative Breast Cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wu, Q., Siddharth, S., and Sharma, D. (2021). Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. Cancers, 13.","DOI":"10.3390\/cancers13153697"},{"key":"ref_5","first-page":"001","article-title":"Triple Negative Breast Cancer\u2014An Overview","volume":"2013","author":"Aysola","year":"2013","journal-title":"Hered. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1124\/pharmrev.122.000665","article-title":"Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review","volume":"75","author":"Choupani","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Xiong, N., Wu, H., and Yu, Z. (2024). Advancements and Challenges in Triple-Negative Breast Cancer: A Comprehensive Review of Therapeutic and Diagnostic Strategies. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1405491"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination Strategies with PARP Inhibitors in BRCA-Mutated Triple-Negative Breast Cancer: Overcoming Resistance Mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1470-2045(24)00737-X","article-title":"Darolutamide or Capecitabine in Triple-Negative, Androgen Receptor-Positive, Advanced Breast Cancer (UCBG 3-06 START): A Multicentre, Non-Comparative, Randomised, Phase 2 Trial","volume":"26","author":"Bonnefoi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101595","DOI":"10.1016\/j.xcrm.2024.101595","article-title":"Phase 2 Study of Neoadjuvant Enzalutamide and Paclitaxel for Luminal Androgen Receptor-Enriched TNBC: Trial Results and Insights into \u201cARness\u201d","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.35270","article-title":"Cyclin-Dependent Kinase Inhibitors Enhance Programmed Cell Death Protein 1 Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer by Affecting the Immune Microenvironment","volume":"130","author":"Wu","year":"2024","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41388-023-02892-3","article-title":"Selective Inhibition of CDK9 in Triple Negative Breast Cancer","volume":"43","author":"Mustafa","year":"2024","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15330338241234780","DOI":"10.1177\/15330338241234780","article-title":"Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer","volume":"23","author":"Jaradat","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hassan, A., and Aubel, C. (2025). The PI3K\/Akt\/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies. Cancers, 17.","DOI":"10.3390\/cancers17132232"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117877","DOI":"10.1016\/j.bmc.2024.117877","article-title":"Recent Advancement in Developing Small Molecular Inhibitors Targeting Key Kinase Pathways against Triple-Negative Breast Cancer","volume":"112","author":"Islam","year":"2024","journal-title":"Bioorganic Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary Results from IMpassion131, a Double-Blind, Placebo-Controlled, Randomised Phase III Trial of First-Line Paclitaxel with or without Atezolizumab for Unresectable Locally Advanced\/Metastatic Triple-Negative Breast Cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Long-Term Survival Analysis of the Randomized, Phase 3 DESTINY-Breast04 Trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent Advances in Therapeutic Strategies for Triple-Negative Breast Cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10549-024-07480-x","article-title":"Regional Differences in Neo\/Adjuvant Chemotherapy Timing in Patients with Early-Stage Triple-Negative Breast Cancer in England","volume":"209","author":"Mirza","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.3390\/curroncol31070282","article-title":"BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork","volume":"31","author":"Tinterri","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining Consensus: A Systematic Review Recommends Methodologic Criteria for Reporting of Delphi Studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1370\/afm.1398","article-title":"Influence of Primary Care on Breast Cancer Outcomes Among Medicare Beneficiaries","volume":"10","author":"Roetzheim","year":"2012","journal-title":"Ann. Fam. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., Liu, S., Cao, S., and Li, X. (2018). Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00909"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamainternmed.2014.1322","article-title":"The Role of Testing for BRCA1 and BRCA2 Mutations in Cancer Prevention","volume":"174","author":"McCarthy","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mgg3.464","article-title":"Role of the General Practitioner in the Care of BRCA1 and BRCA2 Mutation Carriers: General Practitioner and Patient Perspectives","volume":"6","author":"Toledano","year":"2018","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/cncr.31998","article-title":"Primary Care Provider-Reported Involvement in Breast Cancer Treatment Decisions","volume":"125","author":"Wallner","year":"2019","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajmg.a.33068","article-title":"The Process of Deciding about Prophylactic Surgery for Breast and Ovarian Cancer: Patient Questions, Uncertainties, and Communication","volume":"152A","author":"Klitzman","year":"2010","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S1470-2045(15)00205-3","article-title":"The Expanding Role of Primary Care in Cancer Control","volume":"16","author":"Rubin","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_33","first-page":"3219","article-title":"A Qualitative Analysis and Development of a Conceptual Model Assessing Financial Toxicity in Cancer Patients Accessing the Universal Healthcare System","volume":"29","author":"Riva","year":"2021","journal-title":"Support. Care Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/83\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:21:43Z","timestamp":1770117703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020083"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020083","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}